Dendrimers as novel systems for delivery of neuropharmaceuticals to the brain

CNS and Neurological Disorders - Drug Targets

Volumn 10, Issue 5, 2011, Pages 576-588

  Beg, Sarwar ^a   Samad, Abdus ^a   Alam, M I ^a   Nazish, Iram ^a  

^a HAMDARD UNIVERSITY   (India)

Author keywords

Blood brain barrier; Boron neutron capture therapy; Brain targeting; Dendrimer

Indexed keywords

10 HYDROXYCAMPTOTHECIN; 5 AMINO SALICYLIC ACID; ANTISENSE OLIGONUCLEOTIDE; CAVEOLIN; CETUXIMAB; CLATHRIN; DENDRIMER; DICLOFENAC; DNA VACCINE; DOCETAXEL; EFAVIRENZ; ES312 DNA VACCINE; FLUOROURACIL; LAMIVUDINE; LEVODOPA; MEFENAMIC ACID; METHOTREXATE; N ACETYL CYSTINE; NANOMATERIAL; NANOPARTICLE; PACLITAXEL; POLY (PROPYLENEIMINE); POLYAMIDOAMINE; POLYETHER COPOLYESTER; PRODRUG; RABIES VIRUS GLYCOPROTEIN; SMALL INTERFERING RNA; SULFADIAZINE; TRANSFERRIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALZHEIMER DISEASE; ARTICLE; BLOOD BRAIN BARRIER; CENTRAL NERVOUS SYSTEM DISEASE; DIELS ALDER REACTION; DRUG BINDING; DRUG DELIVERY SYSTEM; DRUG PENETRATION; DRUG RELEASE; DRUG SYNTHESIS; DRUG TARGETING; ENDOCYTOSIS; GENE TARGETING; HUMAN; MICROENVIRONMENT; MICROVASCULAR ENDOTHELIAL CELL; MOLECULAR DYNAMICS; MOLECULAR INTERACTION; MORPHOLOGY; NANOENCAPSULATION; NEUROPHARMACOLOGY; PARKINSON DISEASE; PRION DISEASE; PROTEIN EXPRESSION;

EID: 79959976472     PISSN: 18715273     EISSN: 19963181     Source Type: Journal    
DOI: 10.2174/187152711796235023     Document Type: Article

References (118)

1. Sahoo, S.K.; Labhasetwar, V. Nanotech approaches to drug delivery and imaging. Drug Discov. Today, 2003, 8, 1112-1120.
2. Roiter, Y.; Minko, S. AFM single molecule experiments at the solid-liquid interface: in situ conformation of adsorbed flexible polyelectrolyte chains. J. Am. Chem. Soc., 2005, 127, 15688-15689.
3. Tomalia, D.A.; Baker, H.; Dewald, J.; Hall, M.; Kallos, G.; Martin, S.; Roeck, J.; Ryder, J.; Smith, P. A new class of polymers-starburst-dendritic macromolecules. Polym. J., 1985, 17, 117-132.
4. Newkome, G.R.; Yao, Z.Q.; Baker, G.R.; Gupta, V.K. Micelles: 1. Cascade molecules-a new approach to micelles-A (27)-arborol. J. Org. Chem., 1985, 50, 2003-2004.
5. Samad, A.; Alam, M.I.; Saxena, K. Dendrimers: A class of polymers in the nanotechnology for the delivery of active pharmaceuticals. Curr. Pharm. Des., 2009, 15, 2958-2969.
6. Matthews, O.A.; Shipway, A.N.; Stoddart, J.F. Dendrimers-Branching out from curiosities into new technologies. Prog. Polym. Sci., 1998, 23, 1-56.
7. Nanjwade, B.K.; Bechra, H.M.; Derkar, G.K.; Manvi, F.V.; Nanjwade, V.K. Dendrimers: Emerging polymers for drug-delivery systems. Eur. J. Pharm. Sci., 2009, 38, 185-196.
8. Bernstein, D.I.; Stanberry, L.R.; Sacks, S.; Ayisi, N.K.; Gong, Y.H.; Ireland, J.; Mumper, R.J.; Holan, G.; Matthews, B.; McCarthy, T.; Bourne, N. Evaluations of unformulated and formulated dendrimer-based microbicide candidates in mouse and guinea pig models of genital herpes. Antimicrob. Agents Chemother., 2003, 47, 3784-3788.
9. Nolte, J. The Human Brain: An Introduction to Its Functional Anatomy. Mosby Inc., St.Louis: MO, 2002.
10. Mokri, B. The monro-kellie hypothesis: applications in CSF volume depletion. Neurology, 2001, 56, 1746-1748.
11. Pardridge, W.M. Brain Drug Targeting: The Future of Brain Drug Development. Cambridge University Press, Cambridge: UK, 2001.
12. Elegton, R.D.; Davis, T.P. Bioavailability and transport of peptides and peptide drugs into the brain. Peptides, 1997, 18, 1431-1439.
13. Brightman, M.W. In: Ultrastructure of Brain Endothelium. Bradbury, M.W.B., Eds.; Physiology and Pharmacology of the Blood-Brain Barrier, Handbook of Experimental Pharmacology; Springer-ver-lag: Berlin, 1992, pp. 1-22.
14. Pardridge, W.M. The blood-brain barrier and neurotherapeutics. NeuroRX, 2005, 2, 1-2.
15. Greig, N. In: Drug Entry into the Brain and its Pharmacologic Manipulation. Bradbury, M.W.B.; Eds.; Handbook of Experimental Pharmacology; Springer-ver-lag: Berlin, 1992, pp. 487-523.
16. Regier, D.A.; Boyd, J.H.; Burke, J.D. Jr.; Rae, D.S.; Myers, J.K.; Kramer, M.; Robins, L.N.; George, L.K.; Karno, M.; Locke, B.Z. One-month prevalence of mental disorders in the United States. Based on five epidemiologic catchment area sites. Arch. Gen. Psychiatry, 1988, 45, 977-986.
17. Lipinski, C.A. Drug-like properties and the causes of poor solubility and poor permeability. J. Pharmacol. Toxicol. Methods, 2000, 44, 235-249.
18. Pardridge, W.M. Why is the global CNS pharmaceutical market so underpenetrated? Drug Discov. Today, 2002, 7, 5-7.
19. Pardridge, W.M. Blood-brain barrier delivery. Drug Discov. Today, 2007, 12(1/2), 54-61.
20. Frechet, J.M.J. Dendrimers and supramolecular chemistry. Proc. Natl. Acad. Sci. USA, 2002, 99, 4782-4787.
21. Esfand, R.; Tomalia, D.A. In: Laboratory Synthesis of Poly(amidoamine)(PAMAM) Dendrimers; Frechet, J.M.J., Eds.; Dendrimers and other Dendritic Polymers; Chichester: Wiley, 2001, pp. 587-604.
22. Tomalia, D.A. Supramolecular chemistry: fluorine makes a difference. Nat. Mater., 2003, 2, 711-712.
23. Lee, J.W.; Kim, J.H.; Kim, H.J.; Han, S.C.; Kim, J.H.; Shin, W.S.; Jin, S.H. Synthesis of symmetrical and unsymmetrical PAMAM dendrimers by fusion between azide and alkyne functionalized PAMAM dendrons. Bioconjug. Chem., 2007, 18, 579-584.
24. Appelhans, D.; Zhong, Y.; Komber, H.; Friedel, P.; Oertel, U.; Scheler, U.; Morgner, N.; Kuckling, D.; Richter, S.; Seidel, J.; Brutschy, B.; Voit, B. Oligosaccharide-modified Poly(propyleneimine) dendrimers: synthesis, structure determination, and Cu(II) complexation. Macromol. Biosci., 2007, 7, 373-383.
25. Barbara, K.; Maria, B. Dendrimers: properties and applications. Acta Biochim. Pol., 2001, 48, 199-208.
26. Sonke, S.; Tomalia, D.A. Dendrimers in biomedical applications reflections on the field. Adv. Drug Deliv. Rev., 2005, 57, 2106-2129.
27. Morgenroth, F.; Mullen, K. Dendritic and hyper branched polyphenylenes via a simple Diels-Alder route. Tetrahedron, 1997, 53, 15349-15366.
28. Franc, G.; Kakkar, A.K. Diels-Alder "Click" chemistry in designing dendritic macromolecules. Chem. Eur. J., 2009, 15, 5630-5639.
29. Killops, K.L.; Campos, L.M.; Hawker, C.J. Robust, efficient, and orthogonal synthesis of dendrimers via thiol-ene. J. Am. Chem. Soc., 2008, 130, 5062-5064.
30. Carlmark, A.; Hawker, C.J.; Hult, A.; Malkoch, M. New methodologies in the construction of dendritic materials. Chem. Soc. Rev., 2009, 38, 352-362.
31. Franc, G.; Kakkar, A.K. Dendrimer design using Cu(I)-Catalyzed alkyne-azide click chemistry. Chem. Comm., 2008, 5267-5276.
32. Antoni, P.; Nystrom, D.; Hawker, C.J.; Hult, A.; Malkoch, M. A chemoselective approach for the accelerated synthesis of well-defined dendritic architectures. Chem. Comm., 2007, 22, 2249-2251.
33. Najlah, M.; D'Emanuele, A. Crossing cellular barriers using dendrimer nanotechnologies. Curr. Opin. Pharmacol., 2006, 6, 522-527.
34. Kolhe, P.; Misra, E.; Kannan, R.M.; Kannan, S.; Lieh-Lai, M. Drug complexation, in vitro release and cellular entry of dendrimers and hyperbranched polymers. Int. J. Pharm., 2003, 259, 143-160.
35. Kannan, S.; Kolhe, P.; Raykova, V.; Glibatec, M.; Kannan, R.M.; Lieh-Lai, M.; Bassett, D. Dynamics of cellular entry and drug delivery by dendritic polymers into human lung epithelial carcinoma cells. J. Biomater. Sci. Polym. Ed., 2004, 15, 311-330.
36. Bhadra, D.; Bhadra, S.; Jain, S.; Jain, N.K. A pegylated dendritic nanoparticulate carrier of fluorouracil. Int. J. Pharm., 2003, 257, 111-124.
37. Ding, B.S.; Dziubla, T.; Shuvaev, V.V.; Muro, S.; Muzykantov, V.R. Advanced drug delivery systems that target the vascular endothelium. Mol. Interv., 2006, 6(2), 98-112.
38. Schroeder, U.; Sommerfeld, P.; Ulrich, S.; Sabel, B.A. Nanoparticle technology for delivery of drugs across the blood-brain barrier. J. Pharm. Sci., 1998, 87, 1305-1307.
39. Kreuter, J. Nanoparticulate systems for brain delivery of drugs. Adv. Drug Deliv. Rev., 2001, 47, 65-81.
40. th March 2010).
41. Shamis, M.; Lode, H.N.; Shabat, D. Bioactivation of self-immolative dendritic prodrugs by catalytic antibody 38C2. J. Am. Chem. Soc., 2004, 126, 1726-1731.
42. Patri, A.K.; Majoros, I.J.; Baker, J.R. Dendritic polymer macromolecular carriers for drug delivery. Curr. Opin. Chem. Biol., 2006, 6, 466-471.
43. Smith, D.K.; Diederich, F. Functional dendrimers: Unique biological mimics. Chem. Eur. J., 1998, 4, 1353-1361.
44. Klajnert, B.; Bryszewska, M. Dendrimers: Properties and applications. Acta Biochim. Pol., 2001, 48, 199-208.
45. Frechet, J.M.J. Functional polymers and dendrimers: Reactivity, molecular architecture, and interfacial energy. Science, 1994, 263, 1710-1715.
46. Jackson, C.L.; Chanzy, H.D.; Booy, F.P.; Drake, B.J.; Tomalia, D.A.; Bauer, B.J.; Amis, E.J. Visualization of dendrimer molecules by transmission electron microscopy (TEM): Staining methods and Cryo-TEM of vitrified solutions. Macromolecules, 1998, 31, 6259-6265.
47. Tang, S.; Martinez, L.J.; Sharma, A.; Chai, M. Synthesis and characterization of water-soluble and photostable L-DOPA dendrimers. Org. Lett., 2006, 8, 4421-4424.
48. Svenson, S. Dendrimers as versatile platform in drug delivery applications. Eur. J. Pharm. Biopharm., 2009, 71, 445-462.
49. Ngwuluka, N.; Pillay, V.; Toit, L.C.D.; Ndesendo, V.; Choonara, Y.; Modi, G.; Naidoo, D. Levodopa delivery systems: advancements in delivery of the gold standard. Expert Opin. Drug Deliv., 2010, 7, 203-224.
50. Lee, C.C.; MacKay, J.A.; Frechet, J.M.; Szoka, F.C. Designing dendrimers for biological applications. Nat. Biotechnol. 2005, 23, 1517-1526.
51. Namazi, H.; Adeli, M. Dendrimers of citric acid and poly (ethylene glycol) as the new drug delivery agents. Biomaterials, 2005, 26, 1175-1183.
52. Ooya, T.; Lee, J.; Park, K. Hydrotropic dendrimers of generations 4 and 5: Synthesis, characterization, and hydrotropic solubilization of paclitaxel. Bioconjugate. Chem., 2004, 15, 1221-1229.
53. Benito, J.M.; Gomez-Garcia, M.; Mellet, C.O.; Baussanne, I.; Defaye, J.; Fernandez, J.M.G. Optimizing saccharide-directed molecular delivery to biological receptors: Design, synthesis, and biological evaluation of glycodendrimer-cyclodextrin conjugates. J. Am. Chem. Soc., 2004, 126, 10355-10363.
54. Morgan, M.T.; Carnahan, M.A.; Immoos, C.E.; Ribeiro, A.A.; Finkelstein, S.; Lee, S.J.; Grinstaff, M.W. Dendritic molecular capsules for hydrophobic compounds. J. Am. Chem. Soc., 2003, 125, 15485-15489.
55. Gillies, E.R.; Frechet, J.M.J. Dendrimers and dendritic polymers in drug delivery. Drug Discov. Today, 2005, 10, 35-43.
56. Saovapakhiran, A.; D'Emanuele, A.; Attwood, D.; Penny, J. Surface modification of PAMAM dendrimers modulates the mechanism of cellular internalization. Bioconj. Chem., 2009, 20, 693-701.
57. Wiwattanapatapee, R.; Carreno-Gomez, B.; Malik, N.; Duncan, R. Anionic PAMAM dendrimers rapidly cross adult rat intestine in vitro: A potential oral delivery system? Pharm. Res., 2000, 17, 991-998.
58. El-Sayed, M.; Ginski, M.; Rhodes, C.; Ghandehari, H. Transepithelial transport of poly(amidoamine) dendrimers across caco-2 cell monolayers. J. Control Release, 2002, 81, 355-365.
59. Jevprasesphant, R.; Penny, J.; Attwood, D.; McKeown, N.B.; ĎEmanuele, A. Engineering of dendrimer surfaces to enhance transepithelial transport and reduce cytotoxicity. Pharm. Res., 2003, 20, 1543-1550.
60. Luo, D.; Haverstick, K.; Belcheva, N.; Han, E.; Saltzman, W.M. Poly(ethyleneglycol)-conjugated PAMAM dendrimer for biocompatible high-efficiency DNA delivery. Macromolecules, 2002, 35, 3456-3462.
61. Braun, C.S.; Vetro, J.A.; Tomalia, D.A.; Koe, G.S.; Koe, J.G.; Middaugh, C.R. Structure/function relationships of polyamideamine/DNA dendrimers as gene delivery vehicles. J. Pharm. Sci., 2005, 94, 423-436.
62. Cheng, Y.; Xu, T. The effect of dendrimers on the Pharmacodynamic and pharmacokinetic behaviours of non-covalently or covalently attached drugs. Eur. J. Med. Chem., 2008, 43, 2291-2297.
63. Kang, H.; DeLong, R.; Fisher, M.H.; Juliano, R.L. Tat-conjugated PAMAM dendrimers as delivery agents for antisense and siRNA oligonucleotides. Pharm. Res., 2005, 22, 2099-2106.
64. Bielinska, A.U.; Chen, C.; Johnson, J.; Baker, J.R., Jr. DNA complexing with polyamidoamine dendrimers: implications for transfection. Bioconjug. Chem., 1999, 10, 843-850.
65. Sarin, H.; Kanevsky, A.S.; Wu, H.; Brimacombe, K.R.; Fung, S.H.; Sousa, A.A.; Auh, S.; Wilson, C.M.; Sharma, K.; Aronova, M.A.; Leapman, R.D.; Griffiths, G.L.; Hall, M.D. Effective transvascular delivery of nanoparticles across the blood-brain tumor barrier into malignant glioma cells. J. Transl. Med., 2008, 6, 80.
66. Choi, J.S.; Nam, K.; Park, J.; Kim, J.B.; Lee, J.K.; Park, J. Enhanced transfection efficiency of PAMAM dendrimer by surface modification with l-arginine. J. Control Release, 2004, 99, 445-456.
67. th March, 2010).
68. Yang, H.; Lopina, S.T.; DiPersio, L.P.; Schmidt, S.P. Stealth dendrimers for drug delivery: correlation between PEGylation, cytocompatibility, and drug payload. J. Mater. Sci.: Mater. Med., 2008, 19, 1991-1997.
69. Prieto, M.J.; Schilrreff, P.; Tesoriero, M.V.; Morilla, M.J.; Romero, E.L. Brain and muscle of Wistar rats are the main targets of intravenous dendrimeric sulfadiazine. Int. J. Pharm., 2008, 360, 204-212.
70. Majoros, I.J.; Myc, A.; Thomas, T.; Mehta, C.B.; Baker, J.R., Jr. PAMAM dendrimer-based multifunctional conjugate for cancer therapy: synthesis, characterization, functionality. Biomacromolecules, 2006, 7, 572-579.
71. Wu, G.; Barth, R.F.; Yang, W.; Kawabata, S.; Zhang, L.; Green-Church, K. Targeted delivery of methotrexate to epidermal growth factor receptor-positive brain tumors by means of cetuximab (IMC-C225) dendrimer bioconjugates. Mol. Cancer Ther., 2006, 5, 52-59.
72. Dhanikula, R.S.; Hammady, T.; Hildgen, P. On the mechanism and dynamics of uptake and permeation of polyether-copolyester dendrimers across an in vitro blood-brain barrier model. J. Pharm. Sci., 2009, 98, 3748-3760.
73. Dhanikula, R.S.; Agarwal, A.; Bouchard, J.F.; Hildgen, P. Methotrexate loaded polyether-copolyester dendrimers for the treatment of gliomas: enhanced efficacy and intratumoral transport capability. Mol. Pharm., 2008, 5, 105-116.
74. Dutta, T.; Garg, M.; Jain, N.K. Targeting of efavirenz loaded tuftsin conjugated poly (propyleneimine) dendrimers to HIV infected macrophages in vitro. Eur. J. Pharm. Sci., 2008, 34, 181-189.
75. Dutta, T.; Jain, N.K. Targeting potential and anti-HIV activity of lamivudine loaded mannosylated poly (propyleneimine) dendrimer. Biochim. Biophys. Acta, 2007, 1770, 681-686.
76. rd; Lin, S.H.; Ferzli, C.; Yu, K.S.; Koski, R.K.; Saul, R.G.; Cronin, P. Starburst dendrimers: enhanced performance and flexibility for immunoassays. Clinical Chem., 1994, 40, 1845-1849.
77. Ding, J.J.; Guo, C.Y.; Cai, Q.L.; Lin, Y.H.; Wang, H. In vivo expression of green fluorescent protein gene and immunogenicity of ES312 vaccine both mediated by starburst polyamidoamine dendrimers. Zhongguo Yi Xue Ke Xue Yuan Xue Bao, 2005, 27, 499-503.
78. Schengrund, C.L. Multivalent saccharides: development of new approaches for inhibiting the effects of glycosphingolipid-binding pathogens. Biochem. Pharmacol., 2003, 65, 699-707.
79. Dutta, T.; Agashe, H.B.; Garg, M.; Balakrishnan, P.; Kabra, M.; Jain, N.K. Poly (propyleneimine) dendrimer based nanocontainers for targeting of efavirenz to human monocytes/macrophages in vitro. J. Drug Target, 2007, 15, 89-98.
80. Ke, W.; Shao, K.; Huang, R.; Han, L.; Liu, Y.; Li, J.; Kuang, Y.; Ye, L.; Lou, J.; Jiang, C. Gene delivery targeted to the brain using an Angiopep-conjugated polyethyleneglycol-modified polyamidoamine dendrimer. Biomaterials, 2009, 30, 6976-6985.
81. Liu, Y.; Huang, R.; Han, L.; Ke, W.; Shao, K.; Ye, L.; Lou, J.; Jiang, C. Brain-targeting gene delivery and cellular internalization mechanisms for modified rabies virus glycoprotein RVG29 nanoparticles. Biomaterials, 2009, 30, 4195-4202.
82. Huang, R.Q.; Qu, Y.H.; Ke, W.L.; Zhu, J.H.; Pei, Y.Y.; Jiang, C. Efficient gene delivery targeted to the brain using a transferrin-conjugated polyethyleneglycol-modified polyamidoamine dendrimer. FASEB J., 2007, 21, 1117-1125.
83. Zhu, S.; Hong, M.; Tang, G.; Qian, L.; Lin, J.; Jiang, Y.; Pei, Y. Partly PEGylated polyamidoamine dendrimer for tumor-selective targeting of doxorubicin: the effects of PEGylation degree and drug conjugation style. Biomaterials, 2010, 31, 1360-1371.
84. Sadler, K.; Tam, J.P. Peptide dendrimers: applications and synthesis. Rev. Mol. Biotechnol., 2002, 90, 195-229.
85. Boyd, B.J.; Kaminskas, L.M.; Karellas, P.; Krippner, G.; Lessene, R.; Porter, C.J.H. Cationic Poly-l-lysine dendrimers: Pharmacokinetics, biodistribution, and evidence for metabolism and bioresorption after intravenous administration to rats. Mol. Pharm., 2006, 3, 614-627.
86. Kaminskas, L.M.; Kelly, B.D.; McLeod, V.M.; Boyd, B.J.; Krippner, G.Y. Pharmacokinetics and tumor disposition of PEGylated, methotrexate conjugated Poly-l-lysine dendrimers. Mol. Pharm., 2009, 6, 1190-1204.
87. Yim, C.B.; Boerman, O.C.; Visser, M.; Jong, M.; Dechesne, A.C.; Rijkers, D.T.; Liskamp, R.M. Versatile conjugation of octreotide to dendrimers by cycloaddition (click) chemistry to yield high-affinity multivalent cyclic peptide dendrimers. Bioconjug. Chem., 2009, 20, 1323-1331.
88. Sideratou, Z.; Tsiourvas, D.; Paleos, C.M. Quaternized Poly(propyleneimine) dendrimers as novel pH-sensitive controlled-release systems. Langmuir, 2000, 16, 1766-1769.
89. Kojima C. Design of stimuli-responsive dendrimers. Expert Opin. Drug Deliv., 2010, 7, 307-319.
90. Medina, S.H.; El-Sayed, M.E.H. Dendrimers as carriers for delivery of chemotherapeutic agents. Chem. Rev., 2009, 109, 3141-3157.
91. Reddy, J.A.; Allagadda, V.M.; Leamon, C.P. Targeting therapeutic and imaging agents to folate receptor positive tumors. Curr. Pharm. Biotechnol., 2005, 6, 131-150.
92. Leamon, C.P.; Reddy, J.A. Folate targeted chemotherapy. Adv. Drug Deliv. Rev., 2004, 56, 1127-1141.
93. Roy, E.J.; Gawlick, U.; Orr, B.A.; Kranz, D.M. Folate-mediated targeting of T cells to tumors. Adv. Drug Deliv. Rev., 2004, 56, 1219-1231.
94. Choi, Y.; Baker, Jr, J.R. Targeting cancer cells with DNA-assembled dendrimers: A mix-and-match strategy for cancer. Cell Cycle, 2005, 4, 669-671.
95. Choi, Y.; Thomas, T.; Kotlyar, A.; Islam, M.T.; Baker, J.R. Synthesis and functional evaluation of DNA assembled polyamidoamine (PAMAM) dendrimer clusters with cancer cell specific targeting. Chem. Biol., 2005, 12, 35-43.
96. Elshakre, M.; Atallah, A.S.; Santos, S.; Grigoras, S. A structural study of carbosilane dendrimers versus polyamidoamine. Comput. Theor. Polym. Sci., 2000, 10, 21-28.
97. 125I-labelled polyamidoamine dendrimers in vivo. J. Control Release, 2006, 65, 133-148.
98. Barth, R.F.; Adams, D.M.; Soloway, A.H.; Alam, F.; Darby, M.V. Boronated starburst dendrimer-monoclonal antibody immunoconjugates: Evaluation as a potential delivery system for neutron captures therapy. Bioconjug. Chem., 1994, 5, 58-66.
99. Liu, L.; Barth, R.F.; Adams, D.M.; Soloway, A.H.;
100. Reisefeld, R.A. Bispecific antibodies as targeting agents for boron neutron capture therapy of brain tumors. J. Hematother., 1995, 4, 477-483.
101. Capala, J.; Barth, R.F.; Bendayam, M.; Lauzon, M.; Adams, D.M.; Soloway, A.H.; Fenstermaker, R.A.; Carlsson, J. Boronated epidermal growth factor as a potential targeting agent for boron neutron capture therapy of brain tumors. Bioconjug. Chem., 1996, 7, 7-15.
102. Wu, G.; Barth, R.F.; Yang, W.; Lee, R.J.; Tjarks, W.; Backer, M.V.; Backer, J.M. Boron containing macromolecules and nanovehicles as delivery agents for neutron capture therapy. Anticancer Agents Med. Chem., 2006, 6, 167-184.
103. Yang, W.; Barth, R.F.; Adams, D.M.; Soloway, A.H. Intratumoral delivery of boronated epidermal growth factor for neutron capture therapy of brain tumors. Cancer Res., 1997, 57, 4333-4339.
104. Wu, G.; Barth, R.F.; Yang, W.; Chatterjee, M.; Tjarks, W.; Ciesielski, M.J.; Fenstermaker, R.A. Site-specific conjugation of boron-containing dendrimers to anti-EGF receptor monoclonal antibody cetuximab (IMC-C225) and its evaluation as a potential delivery agent for neutron capture therapy. Bioconjug. Chem., 2004, 15, 185-194.
105. Wu, G.; Yang, W.; Barth, R.F.; Kawabata, S.; Swindall, M.; Bandyopadhyaya, A.K.; Tjarks, W.; Khorsandi, B.; Blue, T.E.; Ferketich, A.K.; Yang, M.; Christoforidis, G.A.; Sferra, T.J.; Binns, P.J.; Riley, K.J.; Ciesielski, M.J.; Fenstermaker, R.A. Molecular targeting and treatment of an epidermal growth factor receptor-positive glioma using boronated cetuximab. Clin. Cancer Res., 2007, 13, 1260-1268.
106. Yang, W.; Barth, R.F.; Wu, G.; Tjarks, W.; Binns, P.; Riley, K. Boron neutron capture therapy of EGFR or EGFRvIII positive gliomas using either boronated monoclonal antibodies or epidermal growth factor as molecular targeting agents. Appl. Radiat. Isot., 2009, 67, S328-S331.
107. Regino, C.A.S.; Walbridge, S.; Bernardo, M.; Wong, K.J.; Johnson, D.; Lonser, R.; Oldfield, E.H.; Choyke, P.L.; Brechbiel, M.W. A dual CT-MR dendrimer contrast agent as a surrogate marker for convection-enhanced delivery of intracerebral macromolecular therapeutic agents. Contrast Media Mol. Imaging, 2008, 3, 2-8.
108. Klajnert, B.; Arellano, C; Cladera, M.J.; Bryszewska, M. Influence of dendrimer's structure on its activity against amyloid fibril formation. Biochem. Biophys. Res. Commun., 2006, 23, 21-28.
109. Supattapone, S.; Nguyen, H.O.B.; Cohen, F.E.; Prusiner, S.B.; Scott, M.R. Elimination of prions by branched polyamines and implications for therapeutics. Proc. Natl. Acad. Sci. USA, 1999, 96, 14529-14534.
110. Prusiner, S.B. Prions. Proc. Nat. Acad. Sci. USA, 1998, 95, 13363-13383.
111. Supattapone, S.; Wille, H.; Uyechi, L.; Safar, J.; Tremblay, P.; Szoka, F.C.; Cohen, F.E.; Prusiner, S.B.; Scott, M.R. Branched polyamines cure prion-infected neuroblastoma cells. J. Virol, 2001, 75, 3453-3461.
112. Solassol, J.; Crozet, C; Perrier, V.; Leclaire, J.; Beranger, F.; Caminade, A.M.; Meunier, B.; Dormont, D.; Majoral, J.P.; Lehmann, S. Cationic phosphorus-containing dendrimers reduce prion replication both in cell culture and in mice infected with scrapie. J. Gen. Virol, 2004, 85, 791-799.
113. th Mar 2010).
114. Heegaard, P.M.H.; Boas, U.; Otzen, D.E. Dendrimer effects on peptide and protein fibrillation. Macromol. Biosci., 2007, 7, 1047-1059.
115. Cheng, Y.; Xu, T. The effect of dendrimers on the Pharmacodynamic and pharmacokinetic behaviours of non-covalently or covalently attached drugs. Eur. J. Med. Chem., 2008, 43, 2291-2297.
116. Klajnert, B.; Arellano, C; Cladera, M.J.; Bryszewska, M. Influence of dendrimer's structure on its activity against amyloid fibril formation. Biochem. Biophys. Res. Commun., 2006, 23, 21-28.
117. Patel, D.A.; Henry, J.; Good, T.A. Attenuation of p-amyloid induced toxicity by sialic acid-conjugated dendrimeric polymers. Biochim. Biophys. Acta, 2006, 1760, 1802-1809.
118. Patel, D.A.; Henry, J.E.; Good, T.A. Attenuation of p-amyloid-induced toxicity by sialic-acid- conjugated dendrimers: Role of sialic acid attachment. Brain Res., 2007, 1161, 95-105.